Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
Michel Sabé, Toby Pillinger, Stefan Kaiser, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 136, pp. 104608-104608
Open Access | Times Cited: 136
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Inder Kaul, Sharon Sawchak, Christoph U. Correll, et al.
The Lancet (2023) Vol. 403, Iss. 10422, pp. 160-170
Closed Access | Times Cited: 96
Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes
Oliver Howes, Connor Cummings, George E. Chapman, et al.
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 151-167
Open Access | Times Cited: 79
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 59
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 15
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Samantha E. Yohn, Peter J. Weiden, Christian C. Felder, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1098-1112
Open Access | Times Cited: 60
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 59
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
X.M. Hart, Gerhard Gründer, Nicolas Ansermot, et al.
The World Journal of Biological Psychiatry (2024) Vol. 25, Iss. 9, pp. 451-536
Closed Access | Times Cited: 6
Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy
Maria Daniela Ferreira, Joana Duarte, Francisco Veiga, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 678-678
Open Access | Times Cited: 15
A new era for schizophrenia drug development – Lessons for the future
Kiri Granger, Michael Sand, Sheryl Caswell, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103603-103603
Open Access | Times Cited: 14
Treating negative symptoms of schizophrenia: current approaches and future perspectives
Oliver Howes, Paolo Fusar‐Poli, Martin Osugo
The British Journal of Psychiatry (2023) Vol. 223, Iss. 1, pp. 332-335
Open Access | Times Cited: 13
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Marco Solmi, Alessandro Miola, Federico Capone, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1249-1269
Closed Access | Times Cited: 5
Interactions Involving Glycine and Other Amino Acid Neurotransmitters: Focus on Transporter-Mediated Regulation of Release and Glycine–Glutamate Crosstalk
Luca Raiteri
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1518-1518
Open Access | Times Cited: 4
Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
Martin Osugo, Matthew B. Wall, Pierluigi Selvaggi, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
Andrea de Bartolomeis, Mariateresa Ciccarelli, Licia Vellucci, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 2035-2052
Closed Access | Times Cited: 18
Aberrant Brain Dynamics in Schizophrenia During Working Memory Task: Evidence From a Replication Functional MRI Study
Feiwen Wang, Zhening Liu, Sabrina D. Ford, et al.
Schizophrenia Bulletin (2023) Vol. 50, Iss. 1, pp. 96-106
Open Access | Times Cited: 10
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner
Sung Min Yang, Ayan Ghoshal, Jeffrey M. Hubbard, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 7, pp. 1091-1103
Open Access | Times Cited: 9
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Systematic Review and Meta-Analysis
Artur Menegaz de Almeida, Fernanda Moraes Tamashiro, Maria Eduarda Cavalcanti Souza, et al.
Journal of Psychiatric Research (2024) Vol. 181, pp. 262-272
Closed Access | Times Cited: 3
Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
Claudio Brasso, Gianluca Colli, Rodolfo Sgro, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 921-921
Open Access | Times Cited: 8
The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia
Atheeshaan Arumuham, Matthew M. Nour, Mattia Veronese, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 10, pp. 1011-1022
Open Access | Times Cited: 8
Antipsychotics-Loaded Nanometric Emulsions for Brain Delivery
Patrícia C. Pires, Ana Cláudia Paiva‐Santos, Francisco Veiga
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 2174-2174
Open Access | Times Cited: 13
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data
Konstantinos Ν. Fountoulakis, Mauricio Tohen, Carlos A. Zarate
European Neuropsychopharmacology (2024) Vol. 81, pp. 1-9
Closed Access | Times Cited: 2
Psychosis and Schizophrenia
Carol S. Lim, Shreedhar Paudel, Daphne J. Holt, et al.
Elsevier eBooks (2024), pp. 305-320
Closed Access | Times Cited: 2
Graphene quantum dots as eco-friendly fluorescent probes for sensitive and selective determination of lumateperone in pharmaceutical preparation: Greenness and blueness assessment
Arwa Sultan Alqahtani, Farooq M. Almutairi, Muneef M. Aldhafeeri, et al.
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2024) Vol. 327, pp. 125342-125342
Closed Access | Times Cited: 2
Reward processing in schizophrenia and its relation to Mu opioid receptor availability and negative symptoms: A [11C]-carfentanil PET and fMRI study
Ekaterina Shatalina, Hulegar A. Abhishekh, Matthew B. Wall, et al.
NeuroImage Clinical (2023) Vol. 39, pp. 103481-103481
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top